Aortic Stenosis Clinical Trial
— GLUCO-TAVROfficial title:
Glucocorticoid Treatment in Patients Undergoing TAVR to Reduce the Incidence of Atrioventricular Block and Pacemaker Implantation
The goal of this phase IV, randomized, controlled and open-label study is to assess the efficacy of peri-procedure glucocorticoid treatment in the prevention of conduction abnormalities and the need for pacemaker implantation in patients undergoing transaortic valve replacement compared to placebo. Participants randomized to the intervention group will receive a single dose of intravenous Methylprednisolone 7 mg/kg/day on the day of the procedure (1 hour before), followed by 15 mg/12 hours of daily Prednisone for 5 days. The primary endpoint is a composite of permanent pacemaker implantation and the occurrence of new conduction abnormalities (any-degree AV block, bundle branch block, or non-specific intraventricular conduction disorder) at discharge, at 30 days and 1 year.
Status | Recruiting |
Enrollment | 100 |
Est. completion date | September 1, 2024 |
Est. primary completion date | September 1, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A and older |
Eligibility | Inclusion Criteria: - Patients eligible for TAVR implantation according to current European Society of Cardiology guidelines: patients with severe symptomatic aortic stenosis that are > 75 years old or have a high surgical risk. Exclusion Criteria: - Patients with a prior pacemaker. - Patients with contraindications for the use of glucocorticoids including immunosuppression, active or latent infection, documented hypersensitivity or allergy, insulin-dependent diabetes mellitus, glaucoma (both closed-angle and open-angle), recent intestinal perforation, or acute heart failure. - Patients on prior chronic treatment with glucocorticoids (both oral, inhaled, or intravenous, but topical and ophthalmic administration is allowed). - Access for TAVR implantation other than femoral (for example, transapical). - Patients on medication that may interact with glucocorticoids. |
Country | Name | City | State |
---|---|---|---|
Spain | General University Hospital of Alicante | Alicante |
Lead Sponsor | Collaborator |
---|---|
Hospital General Universitario de Alicante |
Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of patients that requiere pacemaker implantation and/or who develop new conduction abnormalities (AV block, bundle branch block, and/or non-specific intraventricular conduction disorder). | One week, 30 days, and 1 year after admission | ||
Secondary | All-cause mortality | One week, 30 days, and 1 year after admission | ||
Secondary | Incidence of strokes (ischemic, hemorrhagic, and/or other unspecified types) | One week, 30 days, and 1 year after admission | ||
Secondary | Incidence of bleeding events requiring transfusion or life-threatening bleeding (BARC 3 or 5) | One week after admission | ||
Secondary | Incidence of major vascular complications | One week and 30 days after admission | ||
Secondary | Length of hospital stay | One week after admission | ||
Secondary | Rate of adverse events related to the use of glucocorticoids | Number of episodes of hyperglycemia, hypertensive crisis, acute decompensated heart failure and local and systemic infections | One week and 30 days after admission | |
Secondary | Pacemaker dependency in patients who have undergone pacemaker implantation | Percentage of stimulation | At 30 days and one year after admission |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04310046 -
Optimal Timing of Transcatheter Aortic Valve Implantation and Percutaneous Coronary Intervention - The TAVI PCI Trial
|
N/A | |
Completed |
NCT03332745 -
Mechanism of Decompensation Evaluation - Aortic Stenosis
|
||
Recruiting |
NCT06008080 -
Post-Market Clinical Follow Up Study With Navitor Valve
|
||
Recruiting |
NCT06055751 -
Long Term Evaluation of Cardiac Arrhythmias After Transcatheter Aortic Valve Implantation -The LOCATE Registry
|
||
Active, not recruiting |
NCT04815785 -
Safety and Efficacy of TaurusOne® Transcatheter Aortic Valve System in Patients With Severe Calcific Aortic Stenosis
|
N/A | |
Terminated |
NCT02202434 -
Safety and Efficacy Study of Lotus Valve for Transcatheter Aortic Valve Replacement
|
N/A | |
Recruiting |
NCT03029026 -
The Role of Occult Cardiac Amyloid in the Elderly With Aortic Stenosis.
|
||
Active, not recruiting |
NCT02903420 -
A Clinical Trial of Transcatheter Aortic Valves in Dialysis Patients (Japan)
|
N/A | |
Completed |
NCT02629328 -
CardioCel Tri-leaflet Repair Study
|
N/A | |
Completed |
NCT02306226 -
Symetis ACURATE Neo™ Valve Implantation SAVI TF Registry
|
||
Withdrawn |
NCT01648309 -
Neuropsychological Testing in Patients Undergoing Transvascular Aortic Valve Implantation
|
N/A | |
Completed |
NCT01676727 -
ADVANCE Direct Aortic Study
|
||
Completed |
NCT01422044 -
Risk Prediction in Aortic Stenosis
|
N/A | |
Withdrawn |
NCT00774657 -
Ventricular Remodeling In Patients With Aortic Stenosis Assessed Echocardiography
|
N/A | |
Terminated |
NCT00535899 -
Speckle Tracking Imaging in Patients With Low Ejection Fraction Aortic Stenosis (SPArKLE-AS)
|
N/A | |
Terminated |
NCT05070130 -
OpSens PRIME CLASS
|
||
Completed |
NCT03314857 -
China XT: Safety and Effectiveness of Edwards Lifesciences SAPIEN XT THV in the Chinese Population
|
N/A | |
Completed |
NCT04157920 -
Impact of Predilatation Between Self-expanding Valves
|
N/A | |
Enrolling by invitation |
NCT06212050 -
Feasibility, Safety, and Effectiveness of the ACURATE neo2 Transcatheter Heart Valve for Severe Bicuspid Aortic Stenosis
|
||
Recruiting |
NCT05893082 -
Multicenter Feasibility Trial of the F2 Filter and Delivery System for Embolic Protection During TAVR
|
N/A |